US/UK/Canada

Share

Pick a time period -
Tags ( Active)

ASTRA Therapeutics raises CHF 7.75 million in seed financing round to advance precision Parasiticides for Animal Health

· Round co-led by MIG Capital (CHF 3 million) and Digitalis Ventures (CHF 3 million), with participation from Borealis Ventures, Kickfund, and Venture Kick. · ASTRA Therapeutics’ proprietary ParaX® platform generates novel precision drugs that target eukaryotic pathogens while sparing host cells. · Eukaryotic pathogens cause illness and death in animals, humans, and crops.Villigen, Switzerland, 24 July 2025 – ASTRA Therapeutics AG, a Swiss biotechnology company developing precision drugs against eukaryotic pathogens, today announced the closing of a CHF 7.75 million seed financing

Lighthouse Tech introduces TAMI – the fashion eyewear frame designed for people who are blind and vision impaired

· TAMI[®], the smart eyewear, designed to help people living with blindness and low vision to navigate safely has been brought to market in Switzerland and Germany · Third Grant awarded by Toyota Mobility Foundation – a rare distinction · Seed Funding Round launched with CHF 1.5 million target; CHF 600,000 already committed; round closing Q3 2025Lugano, Switzerland, 22 May 2025 – Lighthouse Tech SA, the Swiss start-up pioneering smart eyewear, today announced the market entry of TAMI®, the fashion eyewear frame designed specifically for people who are blind or vision impaired.

MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference

PRESS RELEASE   Zurich, Switzerland, January 9, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, will attend the 43rd annual J.P. Morgan Healthcare conference to highlight plans advancing its lead program. MUVON Therapeutics, an award-winning, clinical-stage biotechnology company focused on developing a novel platform for the regeneration of skeletal muscle tissue targeting Stress Urinary Incontinence which affects over 200 million women globally, today announced it has recently received interim data from its ongoing phase 2 clinical

read on light, the ultra-thin reading glasses launched at MIDO, the international eyewear fair in Milan

Zurich, Switzerland, 8 February 2024 – ‘read on’ , a Swiss start-up at the forefront of eyewear innovation, today announced the launch of its latest innovation: ‘read on light’. Ultra-thin, lightweight and highly flexible reading glasses, made of high-quality eyewear material (TR90). At only three millimeters, ‘read on light’ is one of the thinnest reading glasses on the market. ‘read on’ was founded by Sandra Kaufmann and Monika Fink, leaders in the international eyewear business, who established the fashionable Swiss eyewear brand 'Sol Sol Ito' (

Expansion of papilio's international activities

· papilio expands its local presence in Germany by founding papilio Talent Solutions GmbH and integrating the mandates of Voigt Talent Partner · Elena Voigt has been appointed as Managing Director and member of the papilio management team Zurich, Switzerland, 30 January 2024 – papilio, a leading company in the field of talent development, innovative assessment & management development services, and strategic talent consulting, today announced its expansion in the key German market with the founding of papilio Talent Solutions GmbH based in Frankfurt am Main. The German business will be

Breakthrough data for first vaccine against Staphylococcal-induced Toxic Shock Syndrome (TSS) published in eClinicalMedicine, part of The Lancet Discovery Science

· Phase 2 studies showed the TSS1-T vaccine to be safe and effective, offering potential preventative therapy for vulnerable groups and medical workers · Staphylococcal-induced TSS is a serious and life-threatening condition affecting patients with compromised immunity and premenopausal women · Results encouraging for the development of a toxoid-based, multi-component vaccine against sensitive and resistant Staphylococcus aureus infections, a significant threat to patients and financial burden for healthcare systems   Vienna, Austria, 9 January 2024 – The first vaccine to

OM Pharma appoints Roch Ogier as Chief Executive Officer

OM Pharma, a global biopharmaceutical company headquartered in Switzerland, announced the appointment of Roch Ogier as Chief Executive Officer (CEO), effective January 1, 2024. He will succeed Josef Troxler, who will continue to share his expertise as Senior Advisor and Chairman of the Board of the Swiss Affiliate.Geneva, Switzerland, 6 December 2023 - OM Pharma’s Board of Directors has appointed Roch Ogier as Chief Executive Officer (CEO) with effect from January 1, 2024. Roch, currently Chief Operating Officer, brings a wealth of experience in the biotechnology field and across the

Opterion Health closes oversubscribed financing round, securing CHF 6.5m, and announces changes to its Board of Directors

· Opterion Health secures CHF 6.5m commitments to fund ongoing preclinical and Phase I preparation activities to create a new standard in Peritoneal Dialysis (PD) · Financing round supported by private and institutional investors oversubscribed by over 60% · As part of this capital round, additional option capital in the magnitude of CHF 7.3m issued · Stefan Wohlfeil to step down from the Board of Directors · Jan-Anders Karlsson and Robert Leitz elected as new members of the Board of Directors  Muttenz, Switzerland, 20 September 2023 – Opterion Health AG, a Swiss-based

Phase 2 study of breakthrough vaccine against Toxic Shock Syndrome successfully completed

· Phase 2 studies showed the TSS1-T vaccine to be safe and effective, offering potential preventative therapy for vulnerable groups and medical workers · Outcome is also a major step in the battle against MRSA infections · Phase 3 trial preparation underway · Staphylococcal-induced Toxic Shock Syndrome (TSS) is a serious and life-threatening condition affecting at risk patients, including those with compromised immunity and premenopausal women · Methicillin-resistant Staphylococcus aureus (MRSA) is a constant threat to patients and a major financial burden for healthcare

Opterion Health appoints Peter Reinemer as CEO

Muttenz, Switzerland, 18 January 2023 – Opterion Health AG, a Swiss-based life sciences company developing the first major innovation in peritoneal dialysis (PD) for two decades, today announced that Peter Reinemer has been appointed Chief Executive Officer. Currently Chief Technology Officer, Peter will assume the role of CEO in addition to his current position, with effect from 1st February 2023, replacing Björn Englund, who is leaving the company to take a leadership role at a major player in the field of dialysis. Furthermore, Guido Grentzmann, who founded Opterion, has

Stonehaven Consulting and Cozmix merge to become a global life-sciences consultancy group

· Combination creates an international leader in life science consulting, focused on commercial strategy and commercial resource allocation · The new company will be managed by four Partners, Juerg Baggenstoss, Ralph Heuser, Matthias Hofer & Steve Maughan, with George Gunn appointed Chairman · Clients benefit from broadened service & technology offering, additional expertise, and expanded global presence with offices in the USA and in Europe                       Frauenfeld, Switzerland, and Heathrow, Florida, USA, 6 December 2022 – Stonehaven Consulting AG and

Muvon Therapeutics announces First Patient Enrolled in Phase II Clinical Study in Female Patients with Stress Urinary Incontinence using Novel Regenerative Cell Therapy

Zurich, Switzerland, October 27, 2022 – Muvon Therapeutics AG, an innovative clinical-stage biotechnology company, today announced that the first patient with Stress Urinary Incontinence has been enrolled as part of the planned Phase II clinical trial (SUISSE MPC 2-Study) using its novel proprietary cell therapy platform.   This is a randomized blinded clinical study, evaluating the safety and efficacy of a low and high dose of autologous skeletal muscle precursor cell injections into the urethral sphincter muscle of women living with stress urinary incontinence (SUI) with the

Muvon Therapeutics Announces Successful Phase I Clinical Study in Female Patients with Stress Urinary Incontinence using a Novel Regenerative Cell Therapy

Zurich, Switzerland, September 8, 2022 -- Muvon Therapeutics AG, an innovative clinical-stage biotechnology company announced results from a Phase I clinical trial. This first study evaluating a proprietary cell therapy platform demonstrated the safety, feasibility and potential efficacy of autologous skeletal muscle injections into the bladder sphincter of women suffering from Stress Urinary Incontinence with the goal of naturally restoring strength and function over 6 months.Stress Urinary Incontinence (SUI) is defined as the complaint of any involuntary loss of urine on effort or

2bind and Dynamic Biosensors sign technology-service partnership

Munich, Germany, and Regensburg, Germany, 01 September 2022 – Dynamic Biosensors and 2bind, a Contract Research Organization (CRO), today announce that they have signed a technology-service partnership which will enable both companies to further help their customers to accelerate research. The collaboration will enable 2bind to integrate Dynamic Biosensors’ innovative heliX[®] system into its service portfolio, giving Dynamic Biosensors another highly experienced partner in the areas of certified services and beta-testing of future technologies.2bind is a highly respected CRO focused on

Stonehaven Consulting appoints Dr. Ralph Heuser as Partner and announces significant Team Expansion

· Dr. Ralph Heuser brings 20+ years of executive-level international strategic management expertise in animal and human health industries and will lead Stonehaven’s commercial excellence & optimization capabilities · Further enlargement of global team to expand services for clients and meet market demandSwitzerland, 7 April 2022 – Stonehaven Consulting AG, a rapidly growing international consultancy supporting animal and human life sciences companies, today announced the appointment of Dr. Ralph Heuser as a Partner. The Company also announced a number of additional appointments to

Goodly Innovations closes Series A+ financing enabling accelerated development & rollout of its AR (Augmented Reality) supported process guidance system for the pharmaceutical industry

Munich/Landshut, Germany, 7 April 2022 – Goodly Innovations, a software startup specialising in process digitalisation and the use of augmented reality (AR), today announced it has closed a seven-figure Series A+ financing round. Existing investors Bayern Kapital, the venture and growth capital company of the Free State of Bavaria, and BayBG Bayerische Beteiligungsgesellschaft were joined by a family office and a number of business angels. Goodly Innovations is developing and commericalising a system for digitising and managing complex processes using AR technology, significantly improving

Cytosurge launches cell line engineering services based on proprietary FluidFM technology

Zurich, March 30, 2022 – Cytosurge , a global leader in precision single cell manipulation, today announced the launch of FluidFM[®] CellEDIT, a CRISPR cell line engineering service  based on its FluidFM[®] technology. Genetically engineered cell lines have become an invaluable tool in biological research and drug discovery. Nobel-prize winning CRISPR technology has opened up multiple opportunities for generating genome-edited cell lines to be used as disease models, which help the understanding of the biology

R&D project by Cytosurge and the Laboratory of Biosensors and Bioelectronics at the Swiss Federal Institute of Technology receives funding by Innosuisse

Innosuisse is co-funding the collaboration to address a critical bottleneck in the research of pharmacology and the understanding of diseases by automating the creation and handling of single- and multi-cellular biological models in neuroscience.Zurich, January 18, 2022 – Cytosurge , a leading global provider for precision single cell manipulation, is delighted to announce that together with the Laboratory of Biosensors and Bioelectronics (LBB)  at the Swiss Federal Institute of Technology (ETH) in Zurich it has been awarded a

HEMEX Closes Another Successful Financing Round

HEMEX is pleased to announce the successful completion of another fundraising round. Following an oversubscribed first closing in February, our second closing of the Series C increased the round to CHF 7.1 million. · Funds will be used to make initial investments in early-stage life science startups and follow-up in subsequent rounds of its thriving portfolio companies. · Rapidly growing range of services offered to life science startups will be strengthened by hiring several new team members in clinical operations, quality assurance and regulatory affairs. · Investor Club welcomes

AniV8 announces oversubscribed pre-seed funding round

· Funding will accelerate development of wearable monitor to detect osteoarthritis-related pain in companion animals · Backed by experienced seed investors including Irrus Investments, Pro-Vet and Stonehaven Incubate · Seed financing planned for 2022 to further drive product development and commercialization · Investment by Pro-Vet enables for commercialization in China and other Asian countriesDelaware, US, 4 October 2021 – AniV8, a leading developer of clinical sensor technology to diagnose and monitor diseases affecting companion animals, today announced the completion of

OM Pharma wins the 2021 Geneva Economy Award

OM Pharma, a global Geneva-based biopharmaceutical company, leader in the prevention of recurrent respiratory and urinary tract infections, also active in the treatment of vascular diseases, wins the 2021 Geneva Economy AwardGeneva, Switzerland, 21 September 2021 - The award will be presented this evening by the Geneva Chamber of Commerce, Industry and Services (CCIG), the State of Geneva, the Office for the Promotion of Industries and Technologies (OPI) and the Office for the Promotion of Equality and Prevention of Violence (BPEV), during a ceremony at the ‘Bâtiment des Forces Motrices’ in

Opterion Health strengthens its Management Team

Muttenz, Switzerland, 16 September 2021 – Opterion Health AG , a nephrology company focused on innovation in Peritoneal Dialysis (PD), today announced a significant strengthening of its management team, including the appointments of Daniel Lustenberger as Chief Financial Officer (CFO) and Peter Reinemer as Chief Technology Officer (CTO). Mylène Fleurant has been appointed Head of Quality and Ulrike Grimm Head of Project Management. Andreas Schmidt, whom Daniel Lustenberger succeeds as CFO, will continue to support Opterion Health as a partner.Opterion Health is

Anifera awarded seed funding for research from UK’s Centre for Innovation Excellence in Livestock (CIEL)

· Funding will enable Anifera to investigate efficacy of their leading compound to enhance antibiotic treatment for bovine mastitis, a significant economic and welfare challenge for the global dairy industry · Data will support development of a commercialisation plan for their leading compound, globally, with the goal of improving efficacy of older antibiotics and ultimately reducing overall antibiotic usage in livestockLondon, UK, 14 September 2021 – Anifera, a company focused on developing adjunct therapy to improve the efficacy of antibiotics used in animal health, today announced

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media